Fig. 1

Percentage of CXCR4⁺ cells in whole blood is lower in IPF. a PBMCs were isolated from whole blood of 16 patients with idiopathic pulmonary fibrosis (IPF) and 9 age-matched, non-diseased control (NDC) donors where all samples analysed contained more than 5000 CXCR4⁺ cells. b Plasma was isolated from whole blood of 20 patients with idiopathic pulmonary fibrosis (IPF) and 10 age-matched, non-diseased control (NDC) donors. CXCL12 levels were measured by ELISA. c The percentage of CXCR4⁺ (%CXCR4⁺) cells was lower in patients with IPF compared to NDC donors. There was no difference in %CXCR4⁺ between IPF patients on anti-fibrotic therapy (pirfenidone or nintedanib n = 10, ■) or those who were not (n = 6, □) at the time of blood sampling. The percentage of (d) CXCR4⁺/CD4⁺ (e) CXCR4⁺/CD8⁺ cells were lower in IPF compared to NDC but there was no difference in the percentage of (f) CXCR4⁺/CD19⁺ and (g) CXCR4⁺/CD33⁺ cells between the two groups. Data presented as mean and standard deviation. Mann-Whitney U test, *p < 0.05, **p < 0.01, ****p < 0.0001